* is currently hospitalized or in the opinion of the investigator is anticipated to require hospitalization within 48 hours of randomization. * has severe covid-19 or is on supplemental oxygen * has a history of a positive sars-cov-2 antibody serology test * has participated, within the last 30 days, in a clinical study involving an investigational intervention * has received a sars-cov-2 vaccine, monoclonal antibody, or plasma from a person who recovered from covid-19 any time prior to participation in the study note: other protocol defined inclusion/exclusion criteria apply

* is currently hospitalized or in the opinion of the investigator is anticipated to require hospitalization within 48 hours of randomization. * has severe covid-19 or is on supplemental oxygen * has a history of a positive sars-cov-2 antibody serology test * has participated, within the last 30 days, in a clinical study involving an investigational intervention * has received a sars-cov-2 vaccine, monoclonal antibody, or plasma from a person who recovered from covid-19 any time prior to participation in the study note: other protocol defined inclusion/exclusion criteria apply

- is currently hospitalized or in the opinion of the investigator is anticipated to require hospitalization within 48 hours of randomization. - has severe covid-19 or is on supplemental oxygen - has a history of a positive sars-cov-2 antibody serology test - has participated, within the last 30 days, in a clinical study involving an investigational intervention - has received a sars-cov-2 vaccine, monoclonal antibody, or plasma from a person who recovered from covid-19 any time prior to participation in the study note: other protocol defined inclusion/exclusion criteria apply

- is currently hospitalized or in the opinion of the investigator is anticipated to require hospitalization within 48 hours of randomization. - has severe covid-19 or is on supplemental oxygen - has a history of a positive sars-cov-2 antibody serology test - has participated, within the last 30 days, in a clinical study involving an investigational intervention - has received a sars-cov-2 vaccine, monoclonal antibody, or plasma from a person who recovered from covid-19 any time prior to participation in the study note: other protocol defined inclusion/exclusion criteria apply